NIDDK Provides Additional Data From CyNCh Study Evaluating RP103 in Pediatric NASH at AASLD
16 nov. 2015 07h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced researchers have provided additional results from the CyNCh study of RP103 for the treatment...
Raptor Pharmaceutical Completes Acquisition of Quinsair(TM)
05 oct. 2015 07h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has completed the acquisition of Quinsair™ (levofloxacin inhalation solution)...
Raptor Pharmaceutical to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable
23 sept. 2015 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:
Julie Anne Smith,...
Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis
14 sept. 2015 07h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...
Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM)
20 août 2015 17h16 HE
|
Raptor Pharmaceutical Inc
First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis
Approval Received in the European Union and Canada
Expansion of Pipeline with Multiple Late-Stage Orphan Indication...
Raptor Pharmaceutical Receives FDA Approval of Expanded Label for PROCYSBI(R) to Treat Children Aged 2-6 Years With Nephropathic Cystinosis
17 août 2015 07h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced that the U.S. Food and Drug Administration (FDA) approved the expanded use of PROCYSBI®...
Raptor Pharmaceutical to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference
06 mai 2015 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will present at the following conference:
Julie Anne Smith, President and Chief...
Raptor Pharmaceutical to Hold First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, May 7, 2015 at 4:30 p.m. EDT
30 avr. 2015 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2015 financial results on Thursday, May 7, 2015...
Raptor Pharmaceutical to Attend Upcoming Conference
08 avr. 2015 16h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced that Krishna Polu, M.D., Chief Medical Officer, will be a speaker at the following...
Raptor Pharmaceutical Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
08 avr. 2015 12h13 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company focused on developing and commercializing transformative treatments for people...